TECON BIOLOGY Co.LTD (SHE:002100)
China
· Delayed Price · Currency is CNY 6.23
-0.02 (-0.32%)
Apr 29, 2025, 2:45 PM CST
TECON BIOLOGY Co.LTD Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Operating Revenue | 17,176 | 18,973 | 16,958 | 15,663 | 11,960 | Upgrade
|
| Other Revenue | - | 52.75 | 31.07 | 47.43 | 26.81 | Upgrade
|
| Revenue | 17,176 | 19,026 | 16,989 | 15,711 | 11,987 | Upgrade
|
| Revenue Growth (YoY) | -9.72% | 11.99% | 8.14% | 31.07% | 60.33% | Upgrade
|
| Cost of Revenue | 15,090 | 18,965 | 15,375 | 14,595 | 8,592 | Upgrade
|
| Gross Profit | 2,086 | 61.29 | 1,615 | 1,116 | 3,395 | Upgrade
|
| Selling, General & Admin | 987.26 | 1,030 | 971.45 | 1,340 | 1,276 | Upgrade
|
| Research & Development | 200.25 | 252.85 | 176.38 | 167.89 | 101.36 | Upgrade
|
| Other Operating Expenses | -17.26 | 46.8 | 38.72 | 38.33 | 34.64 | Upgrade
|
| Operating Expenses | 1,170 | 1,347 | 1,237 | 1,570 | 1,423 | Upgrade
|
| Operating Income | 915.25 | -1,286 | 377.63 | -454.1 | 1,971 | Upgrade
|
| Interest Expense | - | -245.54 | -248.55 | -206.09 | -196.3 | Upgrade
|
| Interest & Investment Income | - | 60.94 | 64.94 | 46.99 | 49.4 | Upgrade
|
| Other Non Operating Income (Expenses) | -284.34 | -39.41 | -5.87 | -1.9 | -2.04 | Upgrade
|
| EBT Excluding Unusual Items | 630.92 | -1,510 | 188.14 | -615.1 | 1,823 | Upgrade
|
| Impairment of Goodwill | - | -9.58 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | -1.87 | -0 | 0.94 | - | -0.78 | Upgrade
|
| Gain (Loss) on Sale of Assets | 4.5 | 3.9 | 0.23 | -36.72 | -60.29 | Upgrade
|
| Asset Writedown | -22.74 | 0.07 | -0.06 | -48.63 | - | Upgrade
|
| Other Unusual Items | - | 22.44 | 26.79 | 37 | 46.3 | Upgrade
|
| Pretax Income | 610.81 | -1,493 | 216.03 | -663.45 | 1,808 | Upgrade
|
| Income Tax Expense | 14.39 | 23.46 | 26.03 | 31.9 | 22.43 | Upgrade
|
| Earnings From Continuing Operations | 596.42 | -1,516 | 190 | -695.35 | 1,785 | Upgrade
|
| Minority Interest in Earnings | 8.63 | 153.11 | 90.78 | -7.45 | -64.89 | Upgrade
|
| Net Income | 605.05 | -1,363 | 280.78 | -702.79 | 1,720 | Upgrade
|
| Net Income to Common | 605.05 | -1,363 | 280.78 | -702.79 | 1,720 | Upgrade
|
| Net Income Growth | - | - | - | - | 166.94% | Upgrade
|
| Shares Outstanding (Basic) | 1,375 | 1,350 | 1,337 | 1,098 | 1,069 | Upgrade
|
| Shares Outstanding (Diluted) | 1,375 | 1,350 | 1,337 | 1,098 | 1,075 | Upgrade
|
| Shares Change (YoY) | 1.88% | 0.95% | 21.76% | 2.13% | 0.10% | Upgrade
|
| EPS (Basic) | 0.44 | -1.01 | 0.21 | -0.64 | 1.61 | Upgrade
|
| EPS (Diluted) | 0.44 | -1.01 | 0.21 | -0.64 | 1.60 | Upgrade
|
| EPS Growth | - | - | - | - | 166.67% | Upgrade
|
| Free Cash Flow | 535.4 | 750.48 | -1,102 | -219.37 | -1,531 | Upgrade
|
| Free Cash Flow Per Share | 0.39 | 0.56 | -0.82 | -0.20 | -1.42 | Upgrade
|
| Dividend Per Share | - | - | 0.220 | - | 0.460 | Upgrade
|
| Dividend Growth | - | - | - | - | 130.00% | Upgrade
|
| Gross Margin | 12.14% | 0.32% | 9.50% | 7.11% | 28.32% | Upgrade
|
| Operating Margin | 5.33% | -6.76% | 2.22% | -2.89% | 16.45% | Upgrade
|
| Profit Margin | 3.52% | -7.17% | 1.65% | -4.47% | 14.35% | Upgrade
|
| Free Cash Flow Margin | 3.12% | 3.94% | -6.49% | -1.40% | -12.77% | Upgrade
|
| EBITDA | 1,626 | -643.96 | 1,091 | 250.85 | 2,420 | Upgrade
|
| EBITDA Margin | 9.47% | -3.38% | 6.42% | 1.60% | 20.18% | Upgrade
|
| D&A For EBITDA | 711.1 | 641.83 | 713.19 | 704.95 | 448.11 | Upgrade
|
| EBIT | 915.25 | -1,286 | 377.63 | -454.1 | 1,971 | Upgrade
|
| EBIT Margin | 5.33% | -6.76% | 2.22% | -2.89% | 16.45% | Upgrade
|
| Effective Tax Rate | 2.36% | - | 12.05% | - | 1.24% | Upgrade
|
| Revenue as Reported | - | 19,026 | 16,989 | 15,711 | 11,987 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.